001     176974
005     20240229133727.0
024 7 _ |a 10.1200/JCO.21.00784
|2 doi
024 7 _ |a pmid:34618539
|2 pmid
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:114688668
|2 altmetric
037 _ _ |a DKFZ-2021-02207
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Maas, Sybren L N
|0 0000-0002-8745-4405
|b 0
|e First author
245 _ _ |a Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.
260 _ _ |a Alexandria, Va.
|c 2021
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642429767_11680
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B300#LA:B300# / 2021 Dec 1;39(34):3839-3852
520 _ _ |a Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established (CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma.DNA methylation data and copy-number information were generated for 3,031 meningiomas (2,868 patients), and mutation data for 858 samples. DNA methylation subgroups, copy-number variations (CNVs), mutations, and WHO grading were analyzed. Prediction power for outcome was assessed in a retrospective cohort of 514 patients, validated on a retrospective cohort of 184, and on a prospective cohort of 287 multicenter cases.Both CNV- and methylation family-based subgrouping independently resulted in increased prediction accuracy of risk of recurrence compared with the WHO classification (c-indexes WHO 2016, CNV, and methylation family 0.699, 0.706, and 0.721, respectively). Merging all risk stratification approaches into an integrated molecular-morphologic score resulted in further substantial increase in accuracy (c-index 0.744). This integrated score consistently provided superior accuracy in all three cohorts, significantly outperforming WHO grading (c-index difference P = .005). Besides the overall stratification advantage, the integrated score separates more precisely for risk of progression at the diagnostically challenging interface of WHO grade 1 and grade 2 tumors (hazard ratio 4.34 [2.48-7.57] and 3.34 [1.28-8.72] retrospective and prospective validation cohorts, respectively).Merging these layers of histologic and molecular data into an integrated, three-tiered score significantly improves the precision in meningioma stratification. Implementation into diagnostic routine informs clinical decision making for patients with meningioma on the basis of robust outcome prediction.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Stichel, Damian
|0 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
|b 1
|u dkfz
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 2
|u dkfz
700 1 _ |a Sievers, Philipp
|0 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
|b 3
|u dkfz
700 1 _ |a Berghoff, Anna S
|b 4
700 1 _ |a Schrimpf, Daniel
|0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
|b 5
|u dkfz
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 6
|u dkfz
700 1 _ |a Euskirchen, Philipp
|b 7
700 1 _ |a Blume, Christina
|0 P:(DE-He78)a4d58b3605bb0818ae8e3092b8c35182
|b 8
|u dkfz
700 1 _ |a Patel Jamilkhan, Areeba
|0 P:(DE-He78)79506056c05e539af84edf040f0a93ad
|b 9
|u dkfz
700 1 _ |a Dogan, Helin
|0 P:(DE-He78)aa809643fc2092db09b893d4d358a0a6
|b 10
|u dkfz
700 1 _ |a Reuss, David
|0 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa
|b 11
|u dkfz
700 1 _ |a Dohmen, Hildegard
|b 12
700 1 _ |a Stein, Marco
|b 13
700 1 _ |a Reinhardt, Annekathrin
|0 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
|b 14
|u dkfz
700 1 _ |a Suwala, Abigail K
|0 P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c
|b 15
|u dkfz
700 1 _ |a Wefers, Annika
|0 P:(DE-He78)32977c5abc127b0373ece54294a41f63
|b 16
|u dkfz
700 1 _ |a Baumgarten, Peter
|0 0000-0002-2563-2691
|b 17
700 1 _ |a Ricklefs, Franz
|0 0000-0002-1321-6930
|b 18
700 1 _ |a Rushing, Elisabeth J
|0 0000-0001-7616-6320
|b 19
700 1 _ |a Bewerunge-Hudler, Melanie
|0 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
|b 20
|u dkfz
700 1 _ |a Ketter, Ralf
|0 0000-0001-7790-3425
|b 21
700 1 _ |a Schittenhelm, Jens
|0 0000-0002-9168-6209
|b 22
700 1 _ |a Jaunmuktane, Zane
|b 23
700 1 _ |a Leu, Severina
|0 0000-0002-2963-2891
|b 24
700 1 _ |a Greenway, Fay E A
|0 0000-0002-2414-4901
|b 25
700 1 _ |a Bridges, Leslie R
|b 26
700 1 _ |a Jones, Timothy
|0 0000-0003-2037-7334
|b 27
700 1 _ |a Grady, Conor
|b 28
700 1 _ |a Serrano, Jonathan
|0 0000-0002-2839-9573
|b 29
700 1 _ |a Golfinos, John
|b 30
700 1 _ |a Sen, Chandra
|0 0000-0003-1603-2958
|b 31
700 1 _ |a Mawrin, Christian
|b 32
700 1 _ |a Jungk, Christine
|b 33
700 1 _ |a Hänggi, Daniel
|b 34
700 1 _ |a Westphal, Manfred
|b 35
700 1 _ |a Lamszus, Katrin
|0 0000-0002-1381-2353
|b 36
700 1 _ |a Etminan, Nima
|b 37
700 1 _ |a Jungwirth, Gerhard
|b 38
700 1 _ |a Herold-Mende, Christel
|b 39
700 1 _ |a Unterberg, Andreas
|b 40
700 1 _ |a Harter, Patrick
|0 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
|b 41
700 1 _ |a Wirsching, Hans-Georg
|b 42
700 1 _ |a Neidert, Marian C
|b 43
700 1 _ |a Ratliff, Miriam
|b 44
700 1 _ |a Platten, Michael
|b 45
700 1 _ |a Snuderl, Matija
|0 0000-0003-0752-0917
|b 46
700 1 _ |a Aldape, Kenneth D
|0 0000-0001-5119-7550
|b 47
700 1 _ |a Brandner, Sebastian
|0 0000-0002-9821-0342
|b 48
700 1 _ |a Hench, Jürgen
|0 0000-0002-9884-1240
|b 49
700 1 _ |a Frank, Stephan
|b 50
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 51
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 52
|u dkfz
700 1 _ |a Reifenberger, Guido
|0 P:(DE-HGF)0
|b 53
700 1 _ |a Acker, Till
|b 54
700 1 _ |a Wick, Wolfgang
|0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
|b 55
|u dkfz
700 1 _ |a Weller, Michael
|0 0000-0002-1748-174X
|b 56
700 1 _ |a Preusser, Matthias
|0 0000-0003-3541-2315
|b 57
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 58
|u dkfz
700 1 _ |a Sahm, Felix
|0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
|b 59
|u dkfz
700 1 _ |a Meningiomas, German Consortium on Aggressive
|b 60
|e Collaboration Author
773 _ _ |a 10.1200/JCO.21.00784
|g p. JCO.21.00784
|0 PERI:(DE-600)2005181-5
|n 34
|p 3839-3852
|t Journal of clinical oncology
|v 39
|y 2021
|x 1527-7755
909 C O |p VDB
|o oai:inrepo02.dkfz.de:176974
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 0000-0002-8745-4405
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)8aad075b17d93a5636a34942bdbd7ee6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)a4d58b3605bb0818ae8e3092b8c35182
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)79506056c05e539af84edf040f0a93ad
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)aa809643fc2092db09b893d4d358a0a6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)d5149ffd74f42a2fa87a086d66645aaa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)32977c5abc127b0373ece54294a41f63
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 41
|6 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 51
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 52
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 53
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 55
|6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 58
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 59
|6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2019
|d 2021-01-28
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b J CLIN ONCOL : 2019
|d 2021-01-28
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 2
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 3
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l W110 Microarray Unit
|x 4
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK FM zentral
|x 5
920 1 _ |0 I:(DE-He78)B360-20160331
|k B360
|l Pediatric Glioma
|x 6
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK ED ES zentral
|x 7
920 1 _ |0 I:(DE-He78)B320-20160331
|k B320
|l KKE Neuroonkologie
|x 8
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)B360-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)B320-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21